SCHEMBL538171

SCHEMBL538171

CCN(CC)C(=O)c1cccnc1Nc1ccccc1C

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.51
HTT P42858 2/20 0.51
MEN1 O00255 2/20 0.51
ADRA1D P25100 1/20 0.48
ADRA1A P35348 1/20 0.48
ADRA1B P35368 1/20 0.48
SMN1; SMN2 Q16637 3/20 0.47
ALDH1A1 P00352 1/20 0.47
HPGD P15428 1/20 0.47
RAB9A P51151 1/20 0.47
DHODH Q02127 2/20 0.46
MAPT P10636 4/20 0.46
TSHR P16473 2/20 0.46
MAPK1 P28482 1/20 0.46
KDM4E B2RXH2 2/20 0.45
POLB P06746 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
LMNA P02545 2/20 0.45
GHSR Q92847 1/20 0.44
HDAC6 Q9UBN7 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1041912 0.86 MEN1 (0.43) KMT2AHTTMEN1ADRA1DADRA1A
SCHEMBL13134029 0.85 SMN1; SMN2 (0.50) KMT2AHTTMEN1ADRA1DADRA1A
SCHEMBL13748719 0.81 SMN1; SMN2 (0.53) KMT2AHTTMEN1SMN1; SMN2ALDH1A1
SCHEMBL5078987 0.80 SMN1; SMN2 (0.70) KMT2AHTTMEN1SMN1; SMN2ALDH1A1
SCHEMBL7272538 0.79 KDM4E (0.66) KMT2AHTTMEN1SMN1; SMN2ALDH1A1
SCHEMBL27752030 0.76 ADRA1A (0.57) ADRA1DADRA1AADRA1BSMN1; SMN2ALDH1A1
SCHEMBL6644379 0.74 P2RX7 (0.56) ADRA1DADRA1AADRA1BALDH1A1HPGD
SCHEMBL150008 0.74 TSHR (0.75) KMT2AMEN1SMN1; SMN2ALDH1A1HPGD
SCHEMBL29381824 0.74 TSHR (0.75) KMT2AMEN1SMN1; SMN2ALDH1A1HPGD
SCHEMBL7982557 0.74 NPC1 (0.52) KMT2AHTTMEN1ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8349827-B2 Substituted dipyrido-pyrimido-diazepine and benzo-pyrido-pyrimido compounds ARQULE, INC. (US) 2013-01-08 US disclosed
EP-2414360-A1 SUBSTITUTED DIPYRIDO-PYRIMIDO-DIAZEPINE AND BENZO-PYRIDO-PYRIMIDO COMPOUNDS ArQule, Inc. (US) 2012-02-08 EP disclosed
WO-2010114898-A1 SUBSTITUTED DIPYRIDO-PYRIMIDO-DIAZEPINE AND BENZO-PYRIDO-PYRIMIDO COMPOUNDS ARQULE, INC. (US) 2010-10-07 WO disclosed
US-20100249108-A1 SUBSTITUTED DIPYRIDO-PYRIMIDO-DIAZEPINE AND BENZO-PYRIDO-PYRIMIDO COMPOUNDS ARQULE, INC. (US) 2010-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249108-A1 SUBSTITUTED DIPYRIDO-PYRIMIDO-DIAZEPINE AND BENZO-PYRIDO-PYRIMIDO COMPOUNDS PDXK, DPYD, DHFR KMT2A 1921/4885HTT 2273/4885MEN1 513/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.